NO990184L - Fosfinbaserte inhibitorer for matriks-metalloproteaser - Google Patents

Fosfinbaserte inhibitorer for matriks-metalloproteaser

Info

Publication number: NO990184L
Authority: NO; Norway
Prior art keywords: combination; analgesics; cancer; treatment; nsaids
Prior art date: 1996-07-18

Application number

NO990184A

Other languages

English (en)

Norwegian (no)

Other versions

NO990184D0 (no

Inventor

Lawrence Alan Reiter

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-18

Filing date

1999-01-15

Publication date

1999-03-15

1999-01-15 Application filed by Pfizer filed Critical Pfizer

1999-01-15 Publication of NO990184D0 publication Critical patent/NO990184D0/no

1999-03-15 Publication of NO990184L publication Critical patent/NO990184L/no

Links

XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 title 2
102000005741 Metalloproteases Human genes 0.000 title 1
108010006035 Metalloproteases Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
239000011159 matrix material Substances 0.000 title 1
229910000073 phosphorus hydride Inorganic materials 0.000 title 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 3
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 2
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
229940035676 analgesics Drugs 0.000 abstract 2
239000000730 antalgic agent Substances 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
231100000433 cytotoxic Toxicity 0.000 abstract 2
230000001472 cytotoxic effect Effects 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
102000003390 tumor necrosis factor Human genes 0.000 abstract 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
208000030507 AIDS Diseases 0.000 abstract 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 abstract 1
206010014989 Epidermolysis bullosa Diseases 0.000 abstract 1
102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
229930012538 Paclitaxel Natural products 0.000 abstract 1
206010039705 Scleritis Diseases 0.000 abstract 1
206010040047 Sepsis Diseases 0.000 abstract 1
206010040070 Septic Shock Diseases 0.000 abstract 1
208000025865 Ulcer Diseases 0.000 abstract 1
229940009456 adriamycin Drugs 0.000 abstract 1
229930013930 alkaloid Natural products 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
238000002648 combination therapy Methods 0.000 abstract 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
229960005420 etoposide Drugs 0.000 abstract 1
208000002780 macular degeneration Diseases 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
208000028169 periodontal disease Diseases 0.000 abstract 1
229910052697 platinum Inorganic materials 0.000 abstract 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
230000036303 septic shock Effects 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
229940063683 taxotere Drugs 0.000 abstract 1
230000036269 ulceration Effects 0.000 abstract 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
229960004528 vincristine Drugs 0.000 abstract 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/306—Arylalkanephosphinic acids, e.g. Ar-(CH2)n-P(=X)(R)(XH), (X = O,S, Se; n>=1)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65525—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a seven-(or more) membered ring
- C07F9/65527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a seven-(or more) membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)

NO990184A 1996-07-18 1999-01-15 Fosfinbaserte inhibitorer for matriks-metalloproteaser NO990184L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2195996P	1996-07-18	1996-07-18
PCT/IB1997/000800 WO1998003516A1 (fr)	1996-07-18	1997-06-30	Composes a base de phosphinate inhibiteurs des metalloproteases matricielles

Publications (2)

Publication Number	Publication Date
NO990184D0 NO990184D0 (no)	1999-01-15
NO990184L true NO990184L (no)	1999-03-15

Family

ID=21807061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO990184A NO990184L (no)	1996-07-18	1999-01-15	Fosfinbaserte inhibitorer for matriks-metalloproteaser

Country Status (40)

Country	Link
US (1)	US6147061A (fr)
EP (1)	EP0923585B1 (fr)
JP (1)	JP3299975B2 (fr)
KR (1)	KR20000067904A (fr)
CN (1)	CN1225639A (fr)
AP (1)	AP761A (fr)
AR (1)	AR008260A1 (fr)
AT (1)	ATE217315T1 (fr)
AU (1)	AU712973B2 (fr)
BG (1)	BG103111A (fr)
BR (1)	BR9710381A (fr)
CA (1)	CA2260898C (fr)
CO (1)	CO4890852A1 (fr)
CZ (1)	CZ11899A3 (fr)
DE (1)	DE69712496T2 (fr)
DK (1)	DK0923585T3 (fr)
EA (1)	EA199900036A1 (fr)
ES (1)	ES2175415T3 (fr)
GT (1)	GT199700085A (fr)
HN (1)	HN1997000099A (fr)
HR (1)	HRP970391A2 (fr)
HU (1)	HUP9903014A3 (fr)
ID (1)	ID19443A (fr)
IL (1)	IL127567A0 (fr)
IS (1)	IS4928A (fr)
MA (1)	MA24270A1 (fr)
NO (1)	NO990184L (fr)
NZ (1)	NZ333303A (fr)
OA (1)	OA10956A (fr)
PA (1)	PA8433701A1 (fr)
PE (1)	PE88198A1 (fr)
PL (1)	PL331254A1 (fr)
PT (1)	PT923585E (fr)
SI (1)	SI0923585T1 (fr)
SK (1)	SK3799A3 (fr)
TN (1)	TNSN97122A1 (fr)
TR (1)	TR199900066T2 (fr)
WO (1)	WO1998003516A1 (fr)
YU (1)	YU1899A (fr)
ZA (1)	ZA976330B (fr)

Families Citing this family (300)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9912062A (pt)	1998-07-15	2001-04-03	Hassan Jomaa	Compostos orgânicos fosforosos e seu uso
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
FR2788525B1 (fr) *	1999-01-19	2002-11-29	Commissariat Energie Atomique	Pseudo-peptides phosphiniques, utilisables comme inhibiteurs des metalloproteases a zinc matricielles
IL132315A0 (en) *	1999-10-11	2001-03-19	Yissum Res Dev Co	Compositions comprising oxophosphonate-based metalloproteinase inhibitors
UA74803C2 (uk)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6458822B2 (en)	2000-03-13	2002-10-01	Pfizer Inc.	2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
SV2007000775A (es)	2001-01-05	2007-03-15	Pfizer	Anticuerpos contra el receptor del factor de crecimiento similar a insulina
WO2003000194A2 (fr)	2001-06-21	2003-01-03	Pfizer Inc.	Derives bicycliques de pyridine et de pyrimidine utiles en tant qu'agents anticancereux
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
PE20030701A1 (es)	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
WO2003061566A2 (fr) *	2002-01-24	2003-07-31	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Combinaison anticancereuse et son utilisation
JP2005527511A (ja)	2002-03-01	2005-09-15	ファイザーインコーポレイテッド	抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法
SI2275102T1 (sl)	2002-03-13	2015-12-31	Array Biopharma, Inc.	N3 alkilirani benzimidazol derivati kot MEK inhibitorji
UA77303C2 (en)	2002-06-14	2006-11-15	Pfizer	Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
SI1585743T1 (sl)	2002-12-19	2007-08-31	Pfizer	Spojine 2-(1H-indazol-6-ilamino)-benzamida kot inhibitorji protein-kinaz, uporabnih pri zdravljenju očesnih bolezni
AU2003300076C1 (en)	2002-12-30	2010-03-04	Angiotech International Ag	Drug delivery from rapid gelling polymer composition
CN103265477B (zh)	2003-02-26	2017-01-11	苏根公司	作为蛋白激酶抑制剂的氨基杂芳基化合物
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
CN1835975B (zh)	2003-08-13	2012-11-21	辉瑞产品公司	经修饰的人类igf-1r抗体
ATE412655T1 (de)	2003-08-29	2008-11-15	Pfizer	Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
US7144907B2 (en)	2003-09-03	2006-12-05	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
EP2251327B1 (fr)	2003-11-19	2014-02-12	Array Biopharma, Inc.	Inhibiteurs heterocycliques de mek
WO2005051919A1 (fr) *	2003-11-26	2005-06-09	Pfizer Products Inc.	Derives d'aminopyrazole en tant qu'inhibiteurs de la gsk-3
CN101014365B (zh)	2004-07-16	2011-04-13	辉瑞产品公司	使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
PL1786785T3 (pl)	2004-08-26	2010-08-31	Pfizer	Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
MY146381A (en)	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7429667B2 (en)	2005-01-20	2008-09-30	Ardea Biosciences, Inc.	Phenylamino isothiazole carboxamidines as MEK inhibitors
EP2361905B1 (fr)	2005-05-18	2013-03-06	Array Biopharma Inc.	Inhibiteurs hétérocycliques de MEK et leurs utilisation
US20090232879A1 (en)	2005-05-26	2009-09-17	Metabasis Therapeutics, Inc.	Thyromimetics for the Treatment of Fatty Liver Diseases
CA2606498C (fr) *	2005-05-26	2016-08-09	Metabasis Therapeutics, Inc.	Nouvelles substances thyromimetiques contenant de l'acide phosphinique
US8101799B2 (en)	2005-07-21	2012-01-24	Ardea Biosciences	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
JP5055284B2 (ja)	2005-09-20	2012-10-24	オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー	インシュリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
TWI405756B (zh)	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
US7842836B2 (en)	2006-04-11	2010-11-30	Ardea Biosciences	N-aryl-N'alkyl sulfamides as MEK inhibitors
CA2649122C (fr)	2006-04-18	2015-06-30	Ardea Biosciences, Inc.	Sulfonamides pyridone et sulfamides pyridone en tant qu'inhibiteurs de mek
US20080146524A1 (en) *	2006-12-14	2008-06-19	Solvay Pharmaceuticals B.V.	Selective inhibitors of neurotensin degrading enzymes
JP2010513263A (ja)	2006-12-15	2010-04-30	ファイザー・プロダクツ・インク	ベンズイミダゾール誘導体
ES2547303T3 (es)	2007-01-19	2015-10-05	Ardea Biosciences, Inc.	Inhibidores de MEK
JP4782239B2 (ja)	2007-04-18	2011-09-28	ファイザー・プロダクツ・インク	異常細胞増殖治療のためのスルホニルアミド誘導体
US8530463B2 (en)	2007-05-07	2013-09-10	Hale Biopharma Ventures Llc	Multimodal particulate formulations
CA2924418A1 (fr)	2007-07-30	2009-02-05	Jean-Michel Vernier	Derives de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procedes d'utilisation et procedes de preparation de ceux-ci
CL2008003810A1 (es)	2007-12-19	2009-05-22	Genentech Inc	Compuestos derivados de 5-anilino imidazol[1,5-a]piridina o pirazina, inhibidores de la actividad mek quinasa; composiciones farmaceuticas que los contienen; y su uso para tratar trastornos hiperproliferativos y una enfermedad inflamatoria.
BRPI0819505A2 (pt)	2007-12-21	2017-04-04	Genentech Inc	"composto, composição farmacêutica, método para inibir o crescimento celular anormal e método para tratar uma doença inflamatória"
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2240451B1 (fr)	2008-01-04	2017-08-09	Intellikine, LLC	Dérivés d'isoquinoléinone substitués par une purine utiles en tant qu'inhibiteurs de PI3K
WO2009114870A2 (fr)	2008-03-14	2009-09-17	Intellikine, Inc.	Inhibiteurs de kinases, et procédés d’utilisation associés
EP2271347B1 (fr)	2008-03-28	2016-05-11	Hale Biopharma Ventures, Llc	Administration de compositions de benzodiazépine
WO2010006086A2 (fr)	2008-07-08	2010-01-14	Intellikine, Inc.	Inhibiteurs de kinases et procédés d'utilisation
JP5836125B2 (ja)	2008-10-16	2015-12-24	ユニバーシティオブピッツバーグ − オブザコモンウェルスシステムオブハイヤーエデュケイション	高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
AU2010210646B2 (en)	2009-02-05	2015-10-29	Immunogen, Inc.	Novel benzodiazepine derivatives
WO2010090764A1 (fr)	2009-02-09	2010-08-12	Supergen, Inc.	Inhibiteurs pyrrolopyrimidinyle de l'axi kinase
WO2010099139A2 (fr)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Thérapie anti-cancer combinée
JP2012519170A (ja)	2009-02-26	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
US20100222381A1 (en)	2009-02-27	2010-09-02	Hariprasad Vankayalapati	Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
US8465912B2 (en)	2009-02-27	2013-06-18	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (fr)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
JP2012519281A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
CN102448938A (zh)	2009-03-27	2012-05-09	阿迪生物科学公司	作为mek抑制剂的二氢吡啶磺酰胺和二氢吡啶硫酰胺
JP5789252B2 (ja)	2009-05-07	2015-10-07	インテリカイン，エルエルシー	複素環式化合物およびその使用
EP2459191A1 (fr)	2009-07-31	2012-06-06	OSI Pharmaceuticals, LLC	Polythérapie par inhibiteur de mtor et inhibiteur de l angiogenèse
PE20121148A1 (es)	2009-08-17	2012-09-07	Intellikine Llc	Compuestos heterociclicos y usos de los mismos
WO2011027249A2 (fr)	2009-09-01	2011-03-10	Pfizer Inc.	Dérivés de benzimidazole
US9034861B2 (en)	2009-10-13	2015-05-19	Allomek Therapeutics Llc	MEK inhibitors useful in the treatment of diseases
WO2011049625A1 (fr)	2009-10-20	2011-04-28	Mansour Samadpour	Procédé de criblage d'aflatoxine dans des produits
HUE035059T2 (hu)	2009-11-05	2018-05-02	Rhizen Pharmaceuticals S A	Új benzopirán-kinát modulátorok
KR20130009760A (ko)	2010-02-10	2013-01-23	이뮤노젠 아이엔씨	Ｃｄ２０ 항체 및 이의 용도
JP5745283B2 (ja)	2010-02-12	2015-07-08	ファイザー・インク	８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体
AU2011223643A1 (en)	2010-03-03	2012-06-28	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (fr)	2010-03-03	2011-09-09	OSI Pharmaceuticals, LLC	Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
KR101871436B1 (ko)	2010-05-17	2018-06-27	인코젠 쎄라퓨틱스 프라이빗 리미티드	단백질 키나제의 조절제로서의 신규한 3,5-디치환-3ｈ-이미다조[4,5-ｂ]피리딘 및 3,5- 디치환 -3ｈ-[1,2,3]트리아졸로[4,5-ｂ] 피리딘 화합물
AU2011255218B2 (en)	2010-05-21	2015-03-12	Infinity Pharmaceuticals, Inc.	Chemical compounds, compositions and methods for kinase modulation
CN104689314B (zh)	2010-06-16	2018-02-02	高等教育联邦系统-匹兹堡大学	内质蛋白的抗体及其用途
ES2543151T3 (es)	2010-10-20	2015-08-17	Pfizer Inc	Derivados de 2-piridina como moduladores del receptor Smoothened
AU2011326427B2 (en)	2010-11-10	2016-01-07	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
AR084824A1 (es)	2011-01-10	2013-06-26	Intellikine Inc	Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
JP2014510265A (ja)	2011-02-02	2014-04-24	アムジェンインコーポレイテッド	Ｉｇｆ−１ｒの阻害に関する方法および組成物
MY183977A (en)	2011-02-15	2021-03-17	Immunogen Inc	Cytotoxic benzodiazepine derivatives
WO2012116040A1 (fr)	2011-02-22	2012-08-30	OSI Pharmaceuticals, LLC	Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire
JP5808826B2 (ja)	2011-02-23	2015-11-10	インテリカイン，エルエルシー	複素環化合物およびその使用
US9150644B2 (en)	2011-04-12	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
ES2724801T3 (es)	2011-04-19	2019-09-16	Pfizer	Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
WO2012149014A1 (fr)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
ES2710874T3 (es)	2011-05-04	2019-04-29	Rhizen Pharmaceuticals S A	Compuestos novedosos como moduladores de proteína cinasas
CN103796656A (zh)	2011-06-14	2014-05-14	哈尔生物药投资有限责任公司	苯二氮卓的投与
WO2013012918A1 (fr)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Composés hétérocycliques et leurs utilisations
HK1198443A1 (en)	2011-07-19	2015-04-24	无限药品股份有限公司	Heterocyclic compounds and uses thereof
PT3409278T (pt)	2011-07-21	2020-12-18	Sumitomo Dainippon Pharma Oncology Inc	Inibidores de proteína cinase heterocíclicos
WO2013032591A1 (fr)	2011-08-29	2013-03-07	Infinity Pharmaceuticals Inc.	Composés hétérocycliques et leurs utilisations
CA2847540C (fr)	2011-09-22	2016-05-17	Pfizer Inc.	Derives de pyrrolopyrimidine et de purine
US9630979B2 (en)	2011-09-29	2017-04-25	Infinity Pharmaceuticals, Inc.	Inhibitors of monoacylglycerol lipase and methods of their use
WO2013050725A1 (fr)	2011-10-04	2013-04-11	King's College London	Anticorps ige anti-hmw-maa
BR112014011115A2 (pt)	2011-11-08	2017-06-13	Pfizer	métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf
US9452215B2 (en)	2012-02-22	2016-09-27	The Regents Of The University Of Colorado	Bourvadin derivatives and therapeutic uses thereof
WO2013126617A1 (fr)	2012-02-22	2013-08-29	The Regents Of The University Of Colorado, A Body Corporate	Dérivés de bouvardine et leurs utilisations thérapeutiques
CN104321322A (zh)	2012-03-30	2015-01-28	理森制药股份公司	作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
WO2013152252A1 (fr)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Polythérapie antinéoplasique
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US9738724B2 (en)	2012-06-08	2017-08-22	Sutro Biopharma, Inc.	Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (en)	2012-06-26	2017-01-23	Sutro Biopharma Inc	MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
HK1211208A1 (zh)	2012-08-22	2016-05-20	Immunogen, Inc.	細胞毒性苯並二氮呯衍生物
BR112015004022B1 (pt)	2012-08-31	2023-04-25	Sutro Biopharma, Inc	Aminoácidos modificados compreendendo um grupo azido
US9394257B2 (en)	2012-10-16	2016-07-19	Tolero Pharmaceuticals, Inc.	PKM2 modulators and methods for their use
RU2702908C2 (ru)	2012-11-01	2019-10-14	Инфинити Фармасьютикалз, Инк.	Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
WO2014134483A2 (fr)	2013-02-28	2014-09-04	Immunogen, Inc.	Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques
WO2014134486A2 (fr)	2013-02-28	2014-09-04	Immunogen, Inc.	Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques
ES2738493T3 (es)	2013-03-14	2020-01-23	Tolero Pharmaceuticals Inc	Inhibidores de JAK2 y ALK2 y métodos para su uso
WO2014143659A1 (fr)	2013-03-15	2014-09-18	Araxes Pharma Llc	Inhibiteurs covalents irréversibles de la gtpase k-ras g12c
AU2014239542A1 (en)	2013-03-15	2015-10-01	Araxes Pharma Llc	Covalent inhibitors of KRas G12C
US20160024051A1 (en)	2013-03-15	2016-01-28	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9227978B2 (en)	2013-03-15	2016-01-05	Araxes Pharma Llc	Covalent inhibitors of Kras G12C
WO2014151147A1 (fr)	2013-03-15	2014-09-25	Intellikine, Llc	Combinaison d'inhibiteurs de kinase et ses utilisations
MX373584B (es)	2013-05-30	2020-05-05	Infinity Pharmaceuticals Inc	Tratamiento de cánceres utilizando moduladores de la isoforma pi3 cinasa.
WO2014194030A2 (fr)	2013-05-31	2014-12-04	Immunogen, Inc.	Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
ES2658039T3 (es)	2013-07-10	2018-03-08	Sutro Biopharma, Inc.	Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
EP3363800A1 (fr)	2013-10-03	2018-08-22	Kura Oncology, Inc.	Inhibiteurs hétérocycliques d'erk et procédés d'utilisation
WO2015051241A1 (fr)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
EA201690713A1 (ru)	2013-10-04	2016-08-31	Инфинити Фармасьютикалз, Инк.	Гетероциклические соединения и их применения
KR20160076519A (ko)	2013-10-10	2016-06-30	아락세스 파마 엘엘씨	Kras g12c 억제제
JO3805B1 (ar)	2013-10-10	2021-01-31	Araxes Pharma Llc	مثبطات كراس جي12سي
US9840493B2 (en)	2013-10-11	2017-12-12	Sutro Biopharma, Inc.	Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015061204A1 (fr)	2013-10-21	2015-04-30	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
UA115388C2 (uk)	2013-11-21	2017-10-25	Пфайзер Інк.	2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (fr)	2014-04-10	2015-10-15	Pfizer Inc.	Dérivés de dihydropyrrolopyrimidine
WO2015168079A1 (fr)	2014-04-29	2015-11-05	Infinity Pharmaceuticals, Inc.	Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k
KR20160149256A (ko)	2014-04-30	2016-12-27	화이자 인코포레이티드	시클로알킬-결합된 디헤테로사이클 유도체
KR102628356B1 (ko)	2014-06-19	2024-01-24	다케다 야쿠힌 고교 가부시키가이샤	키나제 저해를 위한 헤테로아릴 화합물
WO2016001789A1 (fr)	2014-06-30	2016-01-07	Pfizer Inc.	Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer
EP3473271B1 (fr)	2014-07-31	2022-07-20	The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services	Anticorps monoclonaux humains dirigés contre epha4 et leur utilisation
JO3556B1 (ar)	2014-09-18	2020-07-05	Araxes Pharma Llc	علاجات مدمجة لمعالجة السرطان
WO2016049524A1 (fr)	2014-09-25	2016-03-31	Araxes Pharma Llc	Inhibiteurs de protéines mutantes kras g12c
WO2016049568A1 (fr)	2014-09-25	2016-03-31	Araxes Pharma Llc	Méthodes et compositions permettant l'inhibition de la ras
EP3233829B1 (fr)	2014-12-18	2019-08-14	Pfizer Inc	Dérivés de pyrimidine et de triazine, et leur utilisation comme inhibiteurs d'axl
BR112017021869A2 (pt)	2015-04-10	2018-12-11	Araxes Pharma Llc	compostos quinazolina substituídos e métodos de uso dos mesmos
US10428064B2 (en)	2015-04-15	2019-10-01	Araxes Pharma Llc	Fused-tricyclic inhibitors of KRAS and methods of use thereof
HK1251655A1 (zh)	2015-04-20	2019-02-01	Tolero Pharmaceuticals, Inc.	通过线粒体分析预测对阿伏西地的应答
CN107709344B (zh)	2015-05-01	2022-07-15	共晶制药股份有限公司	用于治疗黄病毒科病毒和癌症的核苷类似物
EP4086264B1 (fr)	2015-05-18	2023-10-25	Sumitomo Pharma Oncology, Inc.	Promédicaments de l'alvocidib à biodisponibilité augmentée
AR104020A1 (es)	2015-06-04	2017-06-21	Kura Oncology Inc	Métodos y composiciones para inhibir la interacción de menina con proteínas mill
WO2017009751A1 (fr)	2015-07-15	2017-01-19	Pfizer Inc.	Dérivés de pyrimidine
US10144724B2 (en)	2015-07-22	2018-12-04	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use thereof
US10568887B2 (en)	2015-08-03	2020-02-25	Tolero Pharmaceuticals, Inc.	Combination therapies for treatment of cancer
CN114230571B (zh)	2015-09-14	2025-07-08	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017058768A1 (fr)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibiteurs de protéines kras portant la mutation g12c
EP3356354A1 (fr)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibiteurs de protéines kras portant la mutation g12c
WO2017058915A1 (fr)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibiteurs de protéines mutantes kras g12c
EP3356339A1 (fr)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibiteurs de protéines mutantes kras g12c
WO2017058728A1 (fr)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibiteurs de protéines kras portant la mutation g12c
EP3356347A1 (fr)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibiteurs de protéines kras portant la mutation g12c
EP3356359B1 (fr)	2015-09-28	2021-10-20	Araxes Pharma LLC	Inhibiteurs de protéines kras portant la mutation g12c
JP2018533939A (ja)	2015-10-19	2018-11-22	アラクセスファーマエルエルシー	Ｒａｓの阻害剤をスクリーニングするための方法
MX2018005967A (es)	2015-11-16	2018-08-29	Araxes Pharma Llc	Compuestos de quinazolina 2-sustituida que comprenden un grupo heterociclico sustituido y metodos de uso de los mismos.
WO2017096165A1 (fr)	2015-12-03	2017-06-08	Agios Pharmaceuticals, Inc.	Inhibiteurs de mat2a pour le traitement du cancer n'exprimant pas mtap
WO2017100546A1 (fr)	2015-12-09	2017-06-15	Araxes Pharma Llc	Procédés de préparation de dérivés de quinazoléine
BR112018015238A2 (pt)	2016-01-27	2018-12-18	Sutro Biopharma Inc	conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição
MX387806B (es)	2016-03-16	2025-03-19	Kura Oncology Inc	Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso
SMT202300273T1 (it)	2016-03-16	2023-09-06	Kura Oncology Inc	Derivati di tieno[2,3–d]pirimidina sostituiti come inibitori di menina–mll e metodi d’uso
US10822312B2 (en)	2016-03-30	2020-11-03	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use
US20170283445A1 (en) *	2016-04-05	2017-10-05	University Of South Carolina	Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
WO2017197240A1 (fr)	2016-05-12	2017-11-16	The Regents Of The University Of Michigan	Inhibiteurs de ash1l et méthodes de traitement au moyen de ceux-ci
US11118233B2 (en)	2016-05-18	2021-09-14	The University Of Chicago	BTK mutation and ibrutinib resistance
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US10646488B2 (en)	2016-07-13	2020-05-12	Araxes Pharma Llc	Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CA3035081A1 (fr)	2016-09-02	2018-03-08	Dana-Farber Cancer Institute, Inc.	Composition et methodes de traitement des dereglements des lymphocytes b
JP2019529484A (ja)	2016-09-29	2019-10-17	アラクセスファーマエルエルシー	Ｋｒａｓｇ１２ｃ変異体タンパク質の阻害剤
US10377743B2 (en)	2016-10-07	2019-08-13	Araxes Pharma Llc	Inhibitors of RAS and methods of use thereof
US11279694B2 (en)	2016-11-18	2022-03-22	Sumitomo Dainippon Pharma Oncology, Inc.	Alvocidib prodrugs and their use as protein kinase inhibitors
BR112019010249A2 (pt)	2016-11-21	2019-09-10	Viking Therapeutics Inc	método de tratamento de doença de armazenamento de glicogênio
WO2018098352A2 (fr)	2016-11-22	2018-05-31	Jun Oishi	Ciblage d'expression du point de contrôle immunitaire induit par kras
MX2019007332A (es)	2016-12-19	2019-11-18	Tolero Pharmaceuticals Inc	Péptidos indicadores y métodos para caracterizar sensibilidad.
EA201991528A1 (ru)	2016-12-22	2020-01-16	Эмджен Инк.	БЕНЗИЗОТИАЗОЛЬНЫЕ, ИЗОТИАЗОЛО[3,4-b]ПИРИДИНОВЫЕ, ХИНАЗОЛИНОВЫЕ, ФТАЛАЗИНОВЫЕ, ПИРИДО[2,3-d]ПИРИДАЗИНОВЫЕ И ПИРИДО[2,3-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ G12C KRAS ДЛЯ ЛЕЧЕНИЯ РАКА ЛЕГКОГО, РАКА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ ИЛИ КОЛОРЕКТАЛЬНОГО РАКА
EP3573971A1 (fr)	2017-01-26	2019-12-04	Araxes Pharma LLC	Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer
WO2018140600A1 (fr)	2017-01-26	2018-08-02	Araxes Pharma Llc	Composés hétéro-hétéro-bicycliques fusionnés et leurs procédés d'utilisation
EP3573970A1 (fr)	2017-01-26	2019-12-04	Araxes Pharma LLC	Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer
CA3051512A1 (fr)	2017-01-26	2018-08-02	Zlip Holding Limited	Unite de liaison a l'antigene cd47 et ses utilisations
WO2018140598A1 (fr)	2017-01-26	2018-08-02	Araxes Pharma Llc	Composés n-hétérocycliques fusionnés et leurs procédés d'utilisation
EP3573954A1 (fr)	2017-01-26	2019-12-04	Araxes Pharma LLC	Composés benzohétéroaromatiques bicycliques fusionnés et leurs procédés d'utilisation
US11358959B2 (en)	2017-01-26	2022-06-14	Araxes Pharma Llc	Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018175746A1 (fr)	2017-03-24	2018-09-27	Kura Oncology, Inc.	Méthodes de traitement d'hémopathies malignes et du sarcome d'ewing
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
JP2020521741A (ja)	2017-05-25	2020-07-27	アラクセスファーマエルエルシー	がんの処置のための化合物およびその使用の方法
US10745385B2 (en)	2017-05-25	2020-08-18	Araxes Pharma Llc	Covalent inhibitors of KRAS
CN110831933A (zh)	2017-05-25	2020-02-21	亚瑞克西斯制药公司	喹唑啉衍生物作为突变kras、hras或nras的调节剂
US11707472B2 (en)	2017-06-05	2023-07-25	Viking Therapeutics, Inc.	Compositions for the treatment of fibrosis
US11542248B2 (en)	2017-06-08	2023-01-03	Kura Oncology, Inc.	Methods and compositions for inhibiting the interaction of menin with MLL proteins
EP3658588A1 (fr)	2017-07-26	2020-06-03	Sutro Biopharma, Inc.	Méthodes d'utilisation d'anticorps anti-cd74 et de conjugués d'anticorps dans le traitement d'un lymphome à cellules t
ES2985118T3 (es)	2017-09-08	2024-11-04	Amgen Inc	Inhibidores de KRAS G12C y métodos de uso de los mismos
JP7196160B2 (ja)	2017-09-12	2022-12-26	スミトモファーマオンコロジー，インコーポレイテッド	Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
WO2019055931A1 (fr)	2017-09-18	2019-03-21	Sutro Biopharma, Inc.	Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations
TW201920170A (zh)	2017-09-20	2019-06-01	美商庫拉腫瘤技術股份有限公司	經取代之menin-mll 抑制劑及使用方法
WO2019075367A1 (fr)	2017-10-13	2019-04-18	Tolero Pharmaceuticals, Inc.	Activateurs de pkm2 en combinaison avec des espèces réactives de l'oxygène pour le traitement du cancer
CN111542318A (zh)	2017-11-10	2020-08-14	密歇根大学董事会	Ash1l降解剂及用其进行治疗的方法
US11324729B2 (en)	2017-12-07	2022-05-10	The Regents Of The University Of Michigan	NSD family inhibitors and methods of treatment therewith
US11787828B2 (en)	2018-03-22	2023-10-17	Viking Therapeutics, Inc.	Crystalline forms and methods of producing crystalline forms of a compound
JP2021524835A (ja)	2018-04-05	2021-09-16	スミトモダイニッポンファーマオンコロジー，インコーポレイテッド	Ａｘｌキナーゼ阻害剤およびその使用
CA3099118A1 (fr)	2018-05-04	2019-11-07	Amgen Inc.	Inhibiteurs de kras g12c et leurs procedes d'utilisation
EP3788038B1 (fr)	2018-05-04	2023-10-11	Amgen Inc.	Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA52564A (fr)	2018-05-10	2021-03-17	Amgen Inc	Inhibiteurs de kras g12c pour le traitement du cancer
MX2020012731A (es)	2018-06-01	2021-02-22	Amgen Inc	Inhibidores de kras g12c y metodos para su uso.
US11319302B2 (en)	2018-06-07	2022-05-03	The Regents Of The University Of Michigan	PRC1 inhibitors and methods of treatment therewith
EP4268898A3 (fr)	2018-06-11	2024-01-17	Amgen Inc.	Inhibiteurs de kras g12c pour le traitement du cancer
EP3807276B1 (fr)	2018-06-12	2025-12-10	Amgen Inc.	Inhibiteurs de kras g12c comprenant un cycle pipérazine et leur utilisation dans le traitement du cancer
US11040038B2 (en)	2018-07-26	2021-06-22	Sumitomo Dainippon Pharma Oncology, Inc.	Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
US12134620B2 (en)	2018-08-01	2024-11-05	Araxes Pharma Llc	Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
US20220047716A1 (en)	2018-09-17	2022-02-17	Sutro Biopharma, Inc.	Combination therapies with anti-folate receptor antibody conjugates
JP7628305B2 (ja)	2018-10-24	2025-02-10	アラクセスファーマエルエルシー	腫瘍転移を阻害するためのｇ１２ｃ変異体ｋｒａｓタンパク質の阻害剤としての２－（２－アクリロイル－２，６－ジアザスピロ［３．４］オクタン－６－イル）－６－（１ｈ－インダゾール－４－イル）－ベンゾニトリル誘導体および関連化合物
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7454572B2 (ja)	2018-11-19	2024-03-22	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤及びその使用方法
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3887373A1 (fr)	2018-11-29	2021-10-06	Araxes Pharma LLC	Composés et procédés d'utilisation associés pour le traitement du cancer
AU2019391097B2 (en)	2018-12-04	2025-07-03	Sumitomo Pharma America, Inc.	CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020117962A1 (fr)	2018-12-05	2020-06-11	Viking Therapeutics, Inc.	Compositions pour le traitement de la fibrose et de l'inflammation
US12459932B2 (en)	2018-12-20	2025-11-04	Amgen Inc.	KIF18A inhibitors
US12441736B2 (en)	2018-12-20	2025-10-14	Amgen Inc.	KIF18A inhibitors
KR102875569B1 (ko)	2018-12-20	2025-10-23	암젠 인크	Kif18a 억제제
MX419368B (es)	2018-12-20	2025-01-14	Amgen Inc	Heteroarilamidas utiles como inhibidores de kif18a
NZ778055A (en)	2019-02-12	2025-11-28	Sumitomo Pharma America Inc	Formulations comprising heterocyclic protein kinase inhibitors
WO2020180768A1 (fr)	2019-03-01	2020-09-10	Revolution Medicines, Inc.	Composés hétéroaryle bicycliques et leurs utilisations
EP3930845A1 (fr)	2019-03-01	2022-01-05	Revolution Medicines, Inc.	Composés hétérocyclyle bicycliques et leurs utilisations
JP2022525149A (ja)	2019-03-20	2022-05-11	スミトモダイニッポンファーマオンコロジー，インコーポレイテッド	ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
EP3941463A1 (fr)	2019-03-22	2022-01-26	Sumitomo Dainippon Pharma Oncology, Inc.	Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant
US20220362394A1 (en)	2019-05-03	2022-11-17	Sutro Biopharma, Inc.	Anti-bcma antibody conjugates
EP3738593A1 (fr)	2019-05-14	2020-11-18	Amgen, Inc	Dosage d'inhibiteur de kras pour le traitement de cancers
KR20250159270A (ko)	2019-05-21	2025-11-10	암젠 인크	고체 상태 형태
JP2022539208A (ja)	2019-07-03	2022-09-07	スミトモファーマオンコロジー，インコーポレイテッド	チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
WO2021026099A1 (fr)	2019-08-02	2021-02-11	Amgen Inc.	Inhibiteurs de kif18a
EP4007752B1 (fr)	2019-08-02	2025-09-24	Amgen Inc.	Inhibiteurs de kif18a
WO2021026101A1 (fr)	2019-08-02	2021-02-11	Amgen Inc.	Inhibiteurs de kif18a
WO2021026100A1 (fr)	2019-08-02	2021-02-11	Amgen Inc.	Dérivés de pyridine en tant qu'inhibiteurs de kif18a
US20220402916A1 (en)	2019-09-18	2022-12-22	Merck Sharp & Dohme Corp.	Small molecule inhibitors of kras g12c mutant
TW202126636A (zh)	2019-09-30	2021-07-16	美商阿吉歐斯製藥公司	作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物
MX2022004656A (es)	2019-10-24	2022-05-25	Amgen Inc	Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
MX2022005053A (es)	2019-10-28	2022-05-18	Merck Sharp & Dohme Llc	Inhibidores de peque?as moleculas de mutante g12c de kras.
JP2023515235A (ja)	2019-10-31	2023-04-12	大鵬薬品工業株式会社	４－アミノブタ－２－エンアミド誘導体及びその塩
CN114901366A (zh)	2019-11-04	2022-08-12	锐新医药公司	Ras抑制剂
PH12022550988A1 (en)	2019-11-04	2023-10-09	Revolution Medicines Inc	Ras inhibitors
KR20220109408A (ko)	2019-11-04	2022-08-04	레볼루션 메디슨즈, 인크.	Ras 억제제
WO2021092115A1 (fr)	2019-11-08	2021-05-14	Revolution Medicines, Inc.	Composés hétéroaryles bicycliques et leurs utilisations
AR120457A1 (es)	2019-11-14	2022-02-16	Amgen Inc	Síntesis mejorada del compuesto inhibidor de g12c de kras
CA3161156A1 (fr)	2019-11-14	2021-05-20	Amgen Inc.	Synthese amelioree de composes inhibiteurs de kras g12c
WO2021108683A1 (fr)	2019-11-27	2021-06-03	Revolution Medicines, Inc.	Inhibiteurs de ras covalents et leurs utilisations
WO2021106231A1 (fr)	2019-11-29	2021-06-03	Taiho Pharmaceutical Co., Ltd.	Composé ayant une activité inhibitrice contre la mutation kras g12d
WO2021142026A1 (fr)	2020-01-07	2021-07-15	Revolution Medicines, Inc.	Dosage d'inhibiteurs de shp2 et méthodes de traitement du cancer
WO2021155006A1 (fr)	2020-01-31	2021-08-05	Les Laboratoires Servier Sas	Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations
EP4114852A1 (fr)	2020-03-03	2023-01-11	Sutro Biopharma, Inc.	Anticorps comprenant des étiquettes de glutamine spécifiques à un site, leurs procédés de préparation et d'utilisation
TW202204334A (zh)	2020-04-08	2022-02-01	美商阿吉歐斯製藥公司	Menin抑制劑及治療癌症之使用方法
WO2021204159A1 (fr)	2020-04-08	2021-10-14	Agios Pharmaceuticals, Inc.	Inhibiteurs de ménine et procédés d'utilisation pour le traitement du cancer
WO2021215545A1 (fr)	2020-04-24	2021-10-28	Taiho Pharmaceutical Co., Ltd.	Polythérapie anticancéreuse avec un inhibiteur de n-(1-acryloyl-azétidin-3-yl)-2-((1h-indazol-3-yl) amino) méthyl)-1 h-imidazole-5-carboxamide de kras-g12c
US20230174518A1 (en)	2020-04-24	2023-06-08	Taiho Pharmaceutical Co., Ltd.	Kras g12d protein inhibitors
MX2022016355A (es)	2020-06-18	2023-04-03	Revolution Medicines Inc	Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
CN116113406B (zh)	2020-07-10	2025-08-29	密歇根大学董事会	Gas41抑制剂及其使用方法
AU2021308045B2 (en)	2020-07-15	2024-06-20	Taiho Pharmaceutical Co., Ltd.	Pyrimidine compound-containing combination to be used in tumor treatment
CA3187757A1 (fr)	2020-09-03	2022-03-24	Ethan AHLER	Utilisation d'inhibiteurs de sos1 pour traiter des malignites a mutations de shp2
IL301298A (en)	2020-09-15	2023-05-01	Revolution Medicines Inc	Indole derivatives as RAS inhibitors in cancer therapy
TW202237119A (zh)	2020-12-10	2022-10-01	美商住友製藥腫瘤公司	Ａｌｋ﹘５抑制劑和彼之用途
AU2021409816A1 (en)	2020-12-22	2023-07-06	Qilu Regor Therapeutics Inc.	Sos1 inhibitors and uses thereof
WO2022221227A1 (fr)	2021-04-13	2022-10-20	Nuvalent, Inc.	Hétérocycles amino-substitués pour le traitement de cancers avec des mutations egfr
EP4329818A1 (fr)	2021-04-30	2024-03-06	Celgene Corporation	Polythérapies utilisant un conjugué anticorps-médicament (adc) anti-bcma en combinaison avec un inhibiteur de gamma-sécrétase (gsi)
WO2022235866A1 (fr)	2021-05-05	2022-11-10	Revolution Medicines, Inc.	Inhibiteurs de ras covalents et leurs utilisations
AR125782A1 (es)	2021-05-05	2023-08-16	Revolution Medicines Inc	Inhibidores de ras
AR125787A1 (es)	2021-05-05	2023-08-16	Revolution Medicines Inc	Inhibidores de ras
EP4347041A1 (fr)	2021-05-28	2024-04-10	Taiho Pharmaceutical Co., Ltd.	Petites molécules inhibitrices de protéines mutées par kras
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
WO2023056589A1 (fr)	2021-10-08	2023-04-13	Servier Pharmaceuticals Llc	Inhibiteurs de ménine et procédés d'utilisation pour le traitement du cancer
EP4387610A4 (fr)	2021-10-12	2025-07-09	Peloton Therapeutics Inc	Sultames et sulfamides tricycliques utilisés en tant qu'agents antitumoraux
CN119212994A (zh)	2021-12-17	2024-12-27	建新公司	作为shp2抑制剂的吡唑并吡嗪化合物
EP4227307A1 (fr)	2022-02-11	2023-08-16	Genzyme Corporation	Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2
JP2025509217A (ja)	2022-03-07	2025-04-11	アムジエン・インコーポレーテツド	４－メチル－２－プロパン－２－イル－ピリジン－３－カルボニトリルを調製するための方法
WO2023172940A1 (fr)	2022-03-08	2023-09-14	Revolution Medicines, Inc.	Méthodes de traitement du cancer du poumon réfractaire immunitaire
TW202412755A (zh)	2022-04-25	2024-04-01	美商耐斯泰德醫療公司	促分裂原活化蛋白激酶（ｍｅｋ）抑制劑
CN120504682A (zh)	2022-06-10	2025-08-19	锐新医药公司	大环ras抑制剂
CA3259758A1 (fr)	2022-06-30	2024-01-04	Sutro Biopharma, Inc.	Anticorps anti-ror1 et conjugués d'anticorps, compositions comprenant des anticorps anti-ror1 ou des conjugués d'anticorps, et méthodes de fabrication et d'utilisation d'anticorps anti-ror1 et de conjugués d'anticorps
WO2024010925A2 (fr)	2022-07-08	2024-01-11	Nested Therapeutics, Inc.	Inhibiteurs de protéine kinase activée par mitogène (mek)
JP2025536257A (ja)	2022-10-14	2025-11-05	ブラックダイアモンドセラピューティクス，インコーポレイティド	イソキノリンまたは６－ａｚａ－キノリン誘導体を使用してがんを治療する方法
KR20250164828A (ko)	2023-03-30	2025-11-25	레볼루션 메디슨즈, 인크.	Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
CN121263418A (zh)	2023-04-07	2026-01-02	锐新医药公司	大环ras抑制剂
KR20260005904A (ko)	2023-04-07	2026-01-12	레볼루션 메디슨즈, 인크.	매크로사이클릭 ras 억제제
CN121100123A (zh)	2023-04-14	2025-12-09	锐新医药公司	Ras抑制剂的结晶形式
TW202448897A (zh)	2023-04-14	2024-12-16	美商銳新醫藥公司	Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
AU2024262795A1 (en)	2023-04-24	2025-11-13	Nested Therapeutics, Inc.	Heterocyclic derivative as mitogen-activated protein kinase (mek) inhibitor
TW202508595A (zh)	2023-05-04	2025-03-01	美商銳新醫藥公司	用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
TW202515582A (zh)	2023-08-24	2025-04-16	日商大塚製藥股份有限公司	西區嘧啶(cedazuridine)之固定劑量組合
WO2025080946A2 (fr)	2023-10-12	2025-04-17	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2025081117A2 (fr)	2023-10-13	2025-04-17	Sutro Biopharma, Inc.	Anticorps anti-facteur tissulaire et conjugués d'anticorps, compositions comprenant des anticorps anti-facteur tissulaire ou des conjugués d'anticorps, et méthodes de fabrication et d'utilisation d'anticorps anti-facteur tissulaire et de conjugués d'anticorps
TW202535891A (zh)	2023-10-20	2025-09-16	美商默沙東有限責任公司	Ｋｒａｓ蛋白之小分子抑制劑
WO2025090905A1 (fr)	2023-10-26	2025-05-01	Nested Therapeutics, Inc.	Formes cristallines de 3-[[3-fluoro-2-(méthylsulfamoylamino)-4-pyridyl]méthyl]-7-[(3-fluoro-2-pyridyl)oxy]-4-méthyl-chromén-2-one
TW202542151A (zh)	2023-12-22	2025-11-01	美商銳格醫藥有限公司	Ｓｏｓ１抑制劑及其用途
WO2025240847A1 (fr)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2025250825A1 (fr)	2024-05-30	2025-12-04	Sutro Biopharma, Inc.	Anticorps anti-trop2, compositions comprenant des anticorps anti-trop2 et méthodes de fabrication et d'utilisation d'anticorps anti-trop2
WO2025255438A1 (fr)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025259841A1 (fr)	2024-06-13	2025-12-18	Nested Therapeutics, Inc.	Forme cristalline de 3-[[3-fluoro-2-(méthylsulfamoylamino)-4-pyridyl]méthyl]-7-[(3-fluoro-2-pyridyl)oxy]-4-méthyl-chromén-2-one
WO2025265060A1 (fr)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2026015790A1 (fr)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015796A1 (fr)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015801A1 (fr)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Méthodes de traitement d'une maladie ou d'un trouble liés à ras

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZW23187A1 (en) *	1986-12-15	1988-06-29	Hoffmann La Roche	Phosphinic acid derivatives
CA2058797A1 (fr) *	1991-02-01	1992-08-02	Michael John Broadhurst	Derives d'aminoacide
CA2126687A1 (fr) *	1992-01-15	1993-07-22	Charles G. Caldwell	Derives de substitution peptidyliques renfermant de l'acide phosphonique, agents antidegeneratifs
UA48121C2 (uk) *	1993-11-04	2002-08-15	Сінтекс (С.Ш.А.) Інк.	Інгібітори матричних металопротеаз і фармацетична композиція на їх основі

1997
- 1997-06-30 EA EA199900036A patent/EA199900036A1/ru unknown
- 1997-06-30 TR TR1999/00066T patent/TR199900066T2/xx unknown
- 1997-06-30 IL IL12756797A patent/IL127567A0/xx unknown
- 1997-06-30 SK SK37-99A patent/SK3799A3/sk unknown
- 1997-06-30 YU YU1899A patent/YU1899A/sh unknown
- 1997-06-30 AU AU31042/97A patent/AU712973B2/en not_active Ceased
- 1997-06-30 JP JP50673698A patent/JP3299975B2/ja not_active Expired - Fee Related
- 1997-06-30 AT AT97926182T patent/ATE217315T1/de not_active IP Right Cessation
- 1997-06-30 SI SI9730325T patent/SI0923585T1/xx unknown
- 1997-06-30 EP EP97926182A patent/EP0923585B1/fr not_active Expired - Lifetime
- 1997-06-30 HU HU9903014A patent/HUP9903014A3/hu unknown
- 1997-06-30 BR BR9710381A patent/BR9710381A/pt not_active Application Discontinuation
- 1997-06-30 PT PT97926182T patent/PT923585E/pt unknown
- 1997-06-30 WO PCT/IB1997/000800 patent/WO1998003516A1/fr not_active Ceased
- 1997-06-30 KR KR1019997000356A patent/KR20000067904A/ko not_active Ceased
- 1997-06-30 ES ES97926182T patent/ES2175415T3/es not_active Expired - Lifetime
- 1997-06-30 DE DE69712496T patent/DE69712496T2/de not_active Expired - Fee Related
- 1997-06-30 NZ NZ333303A patent/NZ333303A/en unknown
- 1997-06-30 PL PL97331254A patent/PL331254A1/xx unknown
- 1997-06-30 CZ CZ99118A patent/CZ11899A3/cs unknown
- 1997-06-30 DK DK97926182T patent/DK0923585T3/da active
- 1997-06-30 CN CN97196455A patent/CN1225639A/zh active Pending
- 1997-06-30 CA CA002260898A patent/CA2260898C/fr not_active Expired - Fee Related
- 1997-07-09 PA PA19978433701A patent/PA8433701A1/es unknown
- 1997-07-11 PE PE1997000608A patent/PE88198A1/es not_active Application Discontinuation
- 1997-07-14 HN HN1997000099A patent/HN1997000099A/es unknown
- 1997-07-14 US US08/892,417 patent/US6147061A/en not_active Expired - Fee Related
- 1997-07-15 GT GT199700085A patent/GT199700085A/es unknown
- 1997-07-16 MA MA24717A patent/MA24270A1/fr unknown
- 1997-07-16 TN TNTNSN97122A patent/TNSN97122A1/fr unknown
- 1997-07-16 AR ARP970103192A patent/AR008260A1/es not_active Application Discontinuation
- 1997-07-16 ID IDP972461A patent/ID19443A/id unknown
- 1997-07-17 HR HR60/021,959A patent/HRP970391A2/hr not_active Application Discontinuation
- 1997-07-17 ZA ZA976330A patent/ZA976330B/xx unknown
- 1997-07-17 AP APAP/P/1997/001043A patent/AP761A/en active
- 1997-07-18 CO CO97040976A patent/CO4890852A1/es unknown
1998
- 1998-12-18 IS IS4928A patent/IS4928A/is unknown
1999
- 1999-01-13 OA OA9900007A patent/OA10956A/en unknown
- 1999-01-15 NO NO990184A patent/NO990184L/no not_active Application Discontinuation
- 1999-01-25 BG BG103111A patent/BG103111A/xx unknown

Also Published As

Publication number	Publication date
OA10956A (en)	2001-10-30
ATE217315T1 (de)	2002-05-15
CO4890852A1 (es)	2000-02-28
CZ11899A3 (cs)	1999-11-17
MA24270A1 (fr)	1998-04-01
NZ333303A (en)	2000-06-23
GT199700085A (es)	1999-01-06
AU712973B2 (en)	1999-11-18
DE69712496T2 (de)	2002-08-29
ID19443A (id)	1998-07-09
HN1997000099A (es)	1997-12-28
CA2260898A1 (fr)	1998-01-29
BR9710381A (pt)	1999-08-17
AR008260A1 (es)	1999-12-29
US6147061A (en)	2000-11-14
ES2175415T3 (es)	2002-11-16
JP3299975B2 (ja)	2002-07-08
TR199900066T2 (xx)	1999-04-21
PL331254A1 (en)	1999-07-05
AP761A (en)	1999-09-13
DK0923585T3 (da)	2002-07-01
ZA976330B (en)	1999-01-19
EP0923585A1 (fr)	1999-06-23
AP9701043A0 (en)	1997-07-31
PA8433701A1 (es)	1999-12-27
IL127567A0 (en)	1999-10-28
SI0923585T1 (en)	2002-08-31
EP0923585B1 (fr)	2002-05-08
HUP9903014A3 (en)	2000-08-28
PE88198A1 (es)	1998-12-21
AU3104297A (en)	1998-02-10
CN1225639A (zh)	1999-08-11
JPH11514673A (ja)	1999-12-14
IS4928A (is)	1998-12-18
DE69712496D1 (de)	2002-06-13
YU1899A (sh)	2000-03-21
CA2260898C (fr)	2002-05-14
SK3799A3 (en)	2000-03-13
WO1998003516A1 (fr)	1998-01-29
BG103111A (en)	1999-11-30
HUP9903014A2 (en)	2000-07-28
PT923585E (pt)	2002-08-30
KR20000067904A (ko)	2000-11-25
TNSN97122A1 (fr)	2005-03-15
NO990184D0 (no)	1999-01-15
HRP970391A2 (en)	1998-08-31
EA199900036A1 (ru)	1999-06-24

Publication	Publication Date	Title
NO990184L (no)	1999-03-15	Fosfinbaserte inhibitorer for matriks-metalloproteaser
MY121754A (en)	2006-02-28	Arylsulfonylamino hydroxamic acid derivatives
YU37499A (sh)	2002-09-19	Derivati arilsulfonil hidroksamske kiseline
NO990821L (no)	1999-02-23	Arylsulfonylamino-hydroksaminsyre-derivater
CA2277100A1 (fr)	1998-07-16	Derives de sulfone cyclique
CA2340202A1 (fr)	2000-02-24	Derives d'acide hydroxamique de pipecolate hydroxy
BR9912944A (pt)	2001-05-08	Inibidores de tace
TR199801530T2 (xx)	1998-11-23	VEGF �nhibit�rleri olarak kinazolin t�revleri.
CA2375524A1 (fr)	2000-12-07	Hydroxamides d'acide 3-(aryl-sulfonyl-amino)-tetrahydro-pyrane-3-carboxylique
CA2375513A1 (fr)	2000-12-07	Hydroxamides d'acide 3-(arylsulfonylamino)-tetrahydrofurane-3-carboxylique
ECSP982358A (es)	1998-12-22	Derivados ciclicos de sulfona
ECSP972233A (es)	1998-09-22	Derivados del acido arilsulfonilamino hidroxamico
ECSP982404A (es)	1998-12-29	Derivados de acido arilsulfonil hidroxamico

Legal Events

Date	Code	Title	Description
2002-04-02	FC2A	Withdrawal, rejection or dismissal of laid open patent application